2023 Open Banking and Finance Prediction from Sensedia
Experts Share How Open Banking and Finance will Transform Fintech Service Delivery MIAMI–(BUSINESS WIRE)–Sensedia, a…
Experts Share How Open Banking and Finance will Transform Fintech Service Delivery MIAMI–(BUSINESS WIRE)–Sensedia, a…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA Credit Profile (KCP), a division of KBRA Analytics, is committed to providing…
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty…
SEOUL, South Korea–(BUSINESS WIRE)–#AIDataCompany—INFINIQ demonstrated its sensor fusion annotation technology at the CES 2023 with…
LAS VEGAS–(BUSINESS WIRE)–CES – Quectel Wireless Solutions, a leading global IoT solutions provider, today demonstrates…
LAS VEGAS–(BUSINESS WIRE)–CES – Quectel Wireless Solutions, a global IoT solutions provider, is today demonstrating…
RICHMOND, Va.–(BUSINESS WIRE)–Harris Williams, a global investment bank specializing in M&A advisory services, announces it…
LITTLE ROCK, Ark.–(BUSINESS WIRE)–#BuildingSomethingDifferent–Encore Bancshares, Inc. and its wholly-owned bank subsidiary, Encore Bank, are pleased…
Public Safety Innovator Continues Building Strong Growth Curve MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$KSCP #SecurityRobot—Knightscope, Inc. (Nasdaq:…
— Internal Appointments Reflect Depth of Long-Tenured Leadership Team — MADISON, Wis.–(BUSINESS WIRE)–First Business Financial…
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty…
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit…
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients…
NXC-201 treatment continues to demonstrate 100% complete response rate in 6 relapsed/refractory AL amyloidosis patients…
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the…
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by…
– Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of…
Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of…
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6…